Respiratory Infection Biospecimen Collections
Respiratory infection biospecimens are critical for diagnostic assay development, vaccine research, therapeutic evaluation, and understanding immune responses to viral pathogens. MT Group has extensive experience collecting biospecimens from patients with COVID-19, influenza, RSV, and other respiratory infections, supporting pharmaceutical, biotechnology, and diagnostics companies in developing interventions and tools to combat respiratory diseases. Our respiratory infection collections fall into three main categories: symptomatic acute infection collections capturing swabs and blood during active illness, post-infection immune response studies tracking recovery and antibody development, and vaccination studies monitoring immune responses to vaccines.
Respiratory infection collections require careful attention to seasonality, as most respiratory pathogens circulate predictably during fall and winter months. MT Group works with you during study planning to align collection timelines with disease prevalence peaks, ensuring efficient enrollment when target infections are circulating in the community. Whether you need nasal swabs collected alongside diagnostic testing from symptomatic patients, longitudinal blood specimens tracking immune evolution over months, or pre- and post-vaccination samples characterizing vaccine responses, our established protocols and experienced sites deliver the biospecimens and clinical documentation required for robust respiratory infection research.
Respiratory Infection Biospecimen Collections
Respiratory infection biospecimens are critical for diagnostic assay development, vaccine research, therapeutic evaluation, and understanding immune responses to viral pathogens. MT Group has extensive experience collecting biospecimens from patients with COVID-19, influenza, RSV, and other respiratory infections, supporting pharmaceutical, biotechnology, and diagnostics companies in developing interventions and tools to combat respiratory diseases. Our respiratory infection collections fall into three main categories: symptomatic acute infection collections capturing swabs and blood during active illness, post-infection immune response studies tracking recovery and antibody development, and vaccination studies monitoring immune responses to vaccines.
Respiratory infection collections require careful attention to seasonality, as most respiratory pathogens circulate predictably during fall and winter months. MT Group works with you during study planning to align collection timelines with disease prevalence peaks, ensuring efficient enrollment when target infections are circulating in the community. Whether you need nasal swabs collected alongside diagnostic testing from symptomatic patients, longitudinal blood specimens tracking immune evolution over months, or pre- and post-vaccination samples characterizing vaccine responses, our established protocols and experienced sites deliver the biospecimens and clinical documentation required for robust respiratory infection research.
Types of Respiratory Infection Studies
Symptomatic/Acute Infection Collections
Symptomatic infection collections capture biospecimens from patients presenting to clinical sites with active respiratory symptoms. Research nasal or nasopharyngeal swabs are collected alongside diagnostic swabs when patients seek medical evaluation for their illness. Enrollment criteria can be tailored to target likely infection types through symptom profiles including fever thresholds, cough duration, symptom onset timing (e.g., within 3-5 days), loss of smell or taste, respiratory rate, or other clinical indicators associated with specific pathogens. These symptomatic collections enable diagnostic assay development, viral load studies, and characterization of acute infection biomarkers, though confirmed pathogen identification typically occurs after specimen collection through diagnostic test results.
Post-Infection Immune Response Studies
Post-infection blood collections track immune responses after documented respiratory infections, capturing antibody development, T-cell responses, and immune cell profiles during recovery and convalescence phases. Subjects with confirmed prior infections (verified through medical records or prior positive diagnostic tests) are enrolled for blood specimen collection at defined timepoints post-infection—ranging from weeks to months after initial illness. These studies enable research into duration of immunity, antibody persistence, memory cell formation, and differences in immune responses across demographics or disease severity. Post-infection collections avoid the timing challenges of acute symptomatic collections and allow for planned, scheduled specimen procurement.
FFPE Tumor Blocks & Sections
Vaccination studies monitor immune responses to respiratory virus vaccines including COVID-19, influenza, and RSV vaccines. Collections can include pre-vaccination baseline specimens and post-vaccination samples at multiple timepoints (e.g., 2 weeks, 4 weeks, 3 months, 6 months post-vaccination) to track antibody production, cellular immune responses, and durability of vaccine-induced immunity. Blood specimens are the primary biospecimen type for vaccination studies, processed to plasma, serum, or PBMCs depending on analytical requirements. Vaccination studies can be cross-sectional (single post-vaccination timepoint) or longitudinal (tracking responses over extended periods), and can incorporate booster dose collections when applicable.
Longitudinal Collections
Longitudinal respiratory infection collections track subjects over extended periods—from months to over a year—enabling research into immune response evolution, waning immunity, reinfection patterns, and long-term sequelae. These studies may follow post-infection subjects tracking antibody decay and immune memory, vaccinated individuals monitoring vaccine durability, or cohorts at risk for infection documenting baseline immunity and subsequent exposures. MT Group has successfully executed longitudinal respiratory infection studies including year-long COVID-19 immune response monitoring with 90%+ subject retention rates. Longitudinal collections require proactive subject engagement, flexible scheduling around standard-of-care visits when possible, and consistent follow-up to maintain high retention throughout extended study periods.
Biospecimen Types for Respiratory Infection Research
Nasal and Nasopharyngeal Swabs
Nasal and nasopharyngeal swabs are the primary specimen type for acute respiratory infection collections, capturing viral material directly from the site of infection. Research swabs are collected alongside diagnostic swabs during the same clinical encounter, enabling biospecimen procurement without requiring subjects to return for additional visits. Swabs can be placed into viral transport media, RNA stabilization buffers, or other specimen processing solutions depending on downstream analytical requirements. These swab specimens support diagnostic assay development, viral load quantification, viral sequencing, and pathogen detection research.
Blood Specimens
Blood specimens are routinely collected for respiratory infection research, typically as whole blood with plasma and serum derivatives also available. Blood collections are essential for post-infection immune response studies, vaccination research, and longitudinal monitoring of antibody levels and cellular immunity. Specimens enable antibody titer measurements, neutralization assays, cytokine profiling, and proteomic biomarker discovery. Blood can be collected during acute symptomatic visits alongside swabs, or during scheduled follow-up visits for post-infection and vaccination studies.
Saliva
Saliva specimens offer a non-invasive alternative or complement to nasal swabs for respiratory virus detection and antibody measurements. Saliva collection is particularly useful for longitudinal studies requiring frequent sampling or for research into mucosal immunity. Saliva can be collected at home by subjects or during clinical visits, providing flexibility in collection logistics.
Sputum and Other Respiratory Specimens
Sputum samples and other lower respiratory tract specimens may be available from subjects with productive coughs or those undergoing specific respiratory procedures. These specimens provide access to lower airway viral loads and immune responses distinct from upper respiratory samples. Availability depends on disease severity and clinical presentation, with sputum production more common in certain respiratory infections.
Types of Respiratory Infection Studies
COVID-19
COVID-19 biospecimen collections remain relevant for ongoing research into SARS-CoV-2 variants, long COVID, vaccine responses, and therapeutic development. While COVID-19 now circulates year-round with less pronounced seasonality than early in the pandemic, infection rates still fluctuate with variant emergence and waning population immunity. MT Group has extensive experience with COVID-19 collections spanning symptomatic infections, post-infection immune studies, and vaccination research across multiple vaccine platforms and booster doses.
Influenza
Influenza collections are highly seasonal, with peak circulation typically occurring from late fall through early spring (October through March in the Northern Hemisphere). Planning influenza biospecimen collections requires aligning study timelines with flu season, as enrollment outside peak months is extremely limited. Both influenza A and B strains circulate seasonally, and collections can target specific subtypes through symptom timing and diagnostic confirmation. Influenza vaccination studies should be planned for late summer and fall to capture pre-vaccination baselines and early post-vaccination timepoints during the vaccination season.
Respiratory Syncytial Virus (RSV)
RSV exhibits strong seasonal patterns, typically circulating from fall through early spring with peak activity in winter months. RSV primarily affects young children and older adults, though infections occur across all age groups. Recent availability of RSV vaccines for older adults and pregnant women has created demand for RSV vaccination studies. Like influenza, RSV biospecimen collections must be carefully timed to coincide with community circulation periods when symptomatic cases are presenting to clinical sites.
Other Respiratory Viruses
MT Group can collect biospecimens from patients infected with other respiratory pathogens including rhinovirus, adenovirus, human metapneumovirus, parainfluenza, and coronavirus strains beyond SARS-CoV-2. Many of these viruses also exhibit seasonal patterns, though some circulate year-round at lower levels. Multi-pathogen respiratory panels are often used for diagnostic confirmation, enabling identification of specific viruses from symptomatically enrolled subjects.
Planning Collections Around Seasonality
Successful respiratory infection biospecimen collections require strategic planning around disease prevalence patterns. MT Group works with sponsors 3-6 months in advance of target collection seasons to develop protocols, activate sites, and prepare for rapid enrollment when infections peak. For influenza and RSV, this means finalizing study design by late summer for fall/winter collections. COVID-19's reduced seasonality provides more flexibility but enrollment rates still vary with community transmission levels. Multi-season studies may be necessary to achieve enrollment targets for highly seasonal pathogens, and backup plans should account for unpredictable seasonal severity variations.
Clinical Characterization & Data
Symptom Documentation and Severity Scoring
Comprehensive symptom documentation is essential for characterizing respiratory infections and correlating clinical presentations with biospecimen findings. MT Group captures detailed symptom profiles including fever (temperature and duration), cough (dry vs. productive, severity, duration), shortness of breath, fatigue, loss of smell or taste, sore throat, nasal congestion, body aches, headache, and gastrointestinal symptoms. Symptom onset dates and progression timelines enable precise determination of illness stage at specimen collection. Disease severity can be assessed using validated scoring systems, oxygen saturation levels, hospitalization status, and clinical outcome measures relevant to specific research objectives.
Diagnostic Test Results
Diagnostic test results provide confirmed pathogen identification essential for interpreting biospecimen analyses. MT Group documents results from rapid antigen tests and multi-pathogen respiratory panels performed during clinical care. For symptomatic collections where diagnostic results may not be available at time of specimen shipment, results are provided retroactively once clinical testing is completed, enabling researchers to stratify samples by confirmed infection status.
Vaccination History
Complete vaccination history is documented for all respiratory infection biospecimen collections, including vaccine types, dates of administration, number of doses received, and time elapsed between last vaccination and specimen collection. For vaccination studies, this information is critical for correlating immune responses with vaccine platforms, dosing schedules, and time post-vaccination. For infection studies, vaccination status provides context for breakthrough infections, hybrid immunity, and protection levels. Booster dose history and vaccination of household contacts may also be captured when relevant to study objectives.
Prior Infection History
Documentation of prior respiratory infections helps researchers understand the impact of previous exposures on current immune responses. MT Group captures prior confirmed infections (dates, diagnostic methods, severity), suspected but unconfirmed infections, and any documented long-term sequelae. For COVID-19 studies, detailed reinfection history has been particularly important given multiple waves of variant-driven infections. Prior infection data enables analyses of immune imprinting and differences between infection-naïve and previously exposed populations.
Comorbidities and Risk Factors
Underlying health conditions significantly influence respiratory infection severity, immune responses, and clinical outcomes. MT Group documents relevant comorbidities including diabetes, cardiovascular disease, chronic lung disease, immunocompromising conditions, obesity (BMI), and other risk factors associated with severe respiratory infections. Age, pregnancy status, smoking history, and immunosuppressive medication use are also captured. This comprehensive risk factor documentation enables subgroup analyses and identification of populations with distinct disease trajectories or immune response patterns.
Longitudinal Outcome Tracking
For longitudinal respiratory infection studies, MT Group tracks clinical outcomes over time including symptom resolution, hospitalizations, development of long-term sequelae (e.g., long COVID), subsequent reinfections, and additional vaccinations received during follow-up periods. This prospective outcome data enables research into predictive biomarkers, immune correlates of protection, and long-term health impacts of respiratory infections.
Why Choose MT Group for Respiratory Infection Collections
Experience with Rapid Seasonal Enrollment : Respiratory infection collections require the ability to mobilize quickly when target pathogens begin circulating and enroll efficiently during compressed seasonal windows. MT Group has extensive experience executing influenza, RSV, and COVID-19 collections with rapid site activation and aggressive enrollment during peak infection periods. Our sites understand the urgency of capturing symptomatic cases during limited seasonal windows and are trained to identify and consent eligible subjects quickly during clinical encounters. This experience translates to successful enrollment completion within single seasons rather than requiring multi-year studies to meet targets.
Understanding Diagnostic Workflow Timing Challenges : Symptomatic respiratory infection collections present unique logistical challenges—subjects seek care for diagnosis and typically leave immediately after testing without returning for research procedures. MT Group's protocols are specifically designed around this constraint, enabling research swab collection during the same visit as diagnostic testing and capturing consent before subjects leave clinical sites. Our sites are trained on efficient workflows that integrate research activities into busy clinical settings without disrupting patient care. We understand the narrow window for specimen collection and have developed processes that maximize enrollment success rates.
Proven Longitudinal Retention: Respiratory infection studies frequently require longitudinal follow-up to track immune responses, antibody persistence, or long-term outcomes over months or years. MT Group achieves 90%+ subject retention rates in longitudinal studies through proactive communication, flexible scheduling coordinated with subjects' availability, and consistent engagement throughout extended follow-up periods. Our experience with year-long COVID-19 immune monitoring studies demonstrates our ability to maintain subject participation even in lengthy respiratory infection research protocols. This high retention ensures complete datasets and robust conclusions from longitudinal analyses.
Multiple Pathogen Experience: MT Group has successfully executed biospecimen collections across COVID-19, influenza, RSV, and other respiratory pathogens, bringing deep understanding of pathogen-specific enrollment considerations, seasonal patterns, and clinical presentation differences. This breadth of experience means we can anticipate challenges, design appropriate inclusion/exclusion criteria, and provide realistic feasibility assessments for any respiratory infection collection. Whether you're developing diagnostics for a single pathogen or studying immune responses across multiple respiratory viruses, our multi-pathogen expertise supports your research objectives.
Clinical Data Validation: MT Group's dedicated clinical data team validates all respiratory infection case report forms for completeness and accuracy, ensuring symptom documentation, diagnostic results, vaccination histories, and outcome data meet research quality standards. This rigorous data validation is particularly important for respiratory infection studies where retrospective diagnostic results must be incorporated after specimen shipment and longitudinal data accumulates over extended timeframes. Our quality-focused approach to clinical annotation maximizes the research value of collected biospecimens.
What Our Clients Say
Frequently Asked Questions
How far in advance should respiratory infection studies be planned?
Seasonal respiratory infection collections should be planned 3-6 months before target collection periods to allow time for protocol development, site activation, and materials preparation. For influenza and RSV collections targeting fall/winter seasons, finalize study design by late summer. COVID-19 collections with less pronounced seasonality offer more flexibility but still benefit from advance planning to ensure sites are ready when enrollment begins. Early planning is critical for symptomatic collections that must capture specimens during compressed seasonal windows.
Can you collect confirmed influenza or RSV cases specifically?
Collecting only confirmed influenza or RSV cases is challenging because subjects typically seek care for diagnosis and leave immediately after diagnostic testing. By the time diagnostic results confirm specific infections, subjects have often already departed clinical sites. However, enrollment criteria can be designed to target likely infections through symptom profiles (fever, cough duration, symptom onset timing, loss of smell) that increase probability of specific pathogens. Diagnostic results are provided retroactively, enabling post-collection stratification by confirmed infection status.
What happens if the respiratory season is milder than expected?
Respiratory infection seasons vary in severity and timing from year to year, creating enrollment uncertainty for highly seasonal pathogens. MT Group conducts feasibility assessments based on historical seasonal patterns but cannot guarantee enrollment if community transmission is unusually low. For critical studies, we recommend planning for potential multi-season enrollment or building flexibility into study timelines. Our sites monitor local infection trends and communicate proactively about enrollment pace relative to projections.
Contact MT Group
Complete the form below to discuss your tissue requirements with our experts.
No obligation consultation. Response within one business day.
